65 related articles for article (PubMed ID: 30999109)
1. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.
Hofman V; Rouquette I; Long-Mira E; Piton N; Chamorey E; Heeke S; Vignaud JM; Yguel C; Mazières J; Lepage AL; Bibeau F; Begueret H; Lassalle S; Lalvée S; Zahaf K; Benzaquen J; Poudenx M; Marquette CH; Sabourin JC; Ilié M; Hofman P
J Thorac Oncol; 2019 Jul; 14(7):1204-1212. PubMed ID: 30999109
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Different
Dülger O; Öz B
Balkan Med J; 2023 Sep; 40(5):344-350. PubMed ID: 37318131
[TBL] [Abstract][Full Text] [Related]
3. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls.
Nambirajan A; Sood R; Khatoon W; Malik PS; Mohan A; Jain D
Arch Pathol Lab Med; 2023 Dec; ():. PubMed ID: 38054562
[TBL] [Abstract][Full Text] [Related]
4. Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Bubendorf L; Büttner R; Al-Dayel F; Dietel M; Elmberger G; Kerr K; López-Ríos F; Marchetti A; Öz B; Pauwels P; Penault-Llorca F; Rossi G; Ryška A; Thunnissen E
Virchows Arch; 2016 Nov; 469(5):489-503. PubMed ID: 27535289
[TBL] [Abstract][Full Text] [Related]
5. Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study.
Eren OC; Mericoz CA; Bozkurtlar E; Bulutay P; Baygul A; Kulac I
Am J Clin Pathol; 2024 Jan; 161(1):71-82. PubMed ID: 37681660
[TBL] [Abstract][Full Text] [Related]
6. Incidence of
Mehta A; Saifi M; Batra U; Suryavanshi M; Gupta K
Lung Cancer (Auckl); 2020; 11():19-25. PubMed ID: 32158297
[TBL] [Abstract][Full Text] [Related]
7. Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.
Makarem M; Ezeife DA; Smith AC; Li JJN; Law JH; Tsao MS; Leighl NB
Curr Oncol; 2021 Aug; 28(5):3268-3279. PubMed ID: 34449580
[No Abstract] [Full Text] [Related]
8. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.
Rossi G; Jocollé G; Conti A; Tiseo M; Zito Marino F; Donati G; Franco R; Bono F; Barbisan F; Facchinetti F
Lung Cancer (Auckl); 2017; 8():45-55. PubMed ID: 28740441
[No Abstract] [Full Text] [Related]
9. Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer.
Yang J; Pyo JS; Kang G
Int J Biol Markers; 2018 Jun; ():1724600818772194. PubMed ID: 29874982
[TBL] [Abstract][Full Text] [Related]
10. Correlating ROS1 Protein Expression With
Huang RSP; Gottberg-Williams A; Vang P; Yang S; Britt N; Kaur J; Haberberger J; Danziger N; Owens C; Beckloff SE; Ross JS; Ramkissoon SH
JTO Clin Res Rep; 2021 Feb; 2(2):100100. PubMed ID: 34589979
[TBL] [Abstract][Full Text] [Related]
11. Multiple cerebral infarctions in
Ikushima H; Hiraishi Y; Toriumi K; Ando T; Tamiya H; Ishida J; Amano Y; Kage H; Tanaka G; Nagase T
Respirol Case Rep; 2021 Sep; 9(9):e0831. PubMed ID: 34471540
[TBL] [Abstract][Full Text] [Related]
12. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; Mancheño N; Juan O; Sanz J; Gonzalez-Larriba JL; Atienza-Cuevas L; Arriola-Arellano E; Abdulkader I; Garcia-Gonzalez J; Camacho C; Rodriguez-Abreu D; Teixido C; Reguart N; Gonzalez-Piñeiro A; Lazaro-Quintela M; Lozano MD; Gurpide A; Gomez-Roman J; Lopez-Brea M; Pijuan L; Salido M; Arriola E; Company A; Insa A; Esteban-Rodriguez I; Saiz M; Azkona E; Alvarez R; Artal A; Plaza ML; Aguiar D; Enguita AB; Benito A; Paz-Ares L; Garrido P; Lopez-Rios F
J Thorac Oncol; 2019 Dec; 14(12):2120-2132. PubMed ID: 31349061
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
Wang W; Cheng G; Zhang G; Song Z
Lung Cancer; 2020 Aug; 146():224-229. PubMed ID: 32580101
[TBL] [Abstract][Full Text] [Related]
14. Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.
Nong L; Zhang Z; Xiong Y; Zheng Y; Li X; Li D; He Q; Li T
J Thorac Dis; 2019 Dec; 11(12):4992-5003. PubMed ID: 32030215
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors.
Heydt C; Ruesseler V; Pappesch R; Wagener S; Haak A; Siebolts U; Riedel R; Michels S; Wolf J; Schultheis AM; Rehker J; Buettner R; Merkelbach-Bruse S
J Mol Diagn; 2019 Nov; 21(6):971-984. PubMed ID: 31382035
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
17. Rare molecular subtypes of lung cancer.
Harada G; Yang SR; Cocco E; Drilon A
Nat Rev Clin Oncol; 2023 Apr; 20(4):229-249. PubMed ID: 36806787
[TBL] [Abstract][Full Text] [Related]
18. Correlation of ROS1 Immunohistochemistry With
Huang RSP; Smith D; Le CH; Liu WW; Ordinario E; Manohar C; Lee M; Rajamani J; Truong H; Li J; Choi C; Li J; Pati A; Bubendorf L; Buettner R; Kerr KM; Lopez-Rios F; Marchetti A; Marondel I; Nicholson AG; Öz AB; Pauwels P; Penault-Llorca F; Rossi G; Thunnissen E; Newell AH; Pate G; Menzl I
Arch Pathol Lab Med; 2020 Jun; 144(6):735-741. PubMed ID: 31509456
[TBL] [Abstract][Full Text] [Related]
19. Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.
Li S; Zhang H; Chen T; Zhang X; Shang G
Cancer Med; 2024 Apr; 13(8):e7201. PubMed ID: 38629293
[TBL] [Abstract][Full Text] [Related]
20. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
